🧫

Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

active
experiment Created: 2026-04-02T05:18:40 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-debate-7c7a8ed89fd3
🧫 Experiment Protocol FalsificationNeurodegenerationG3BPcell_lineproposed
# Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small ## Background and Rationale This experiment tests the hypothesis that G3BP proteins contribute to TDP-43 pathological aggregation through mechanisms independent of canonical stress granule formation. While G3BP1/2 are well-established stress granule nucleators, recent evidence suggests they may also facilitate protein aggregation through direct protein-protein interactions or alternative phase separation pathways. The study employs TDP-43 aggregation models that bypass stress granule induction, including chronic low-level expression of aggregation-prone TDP-43 mutants (A315T, M337V) or treatment with aggregation-promoting conditions (hyperosmotic stress, proteasome inhibition) that don't trigger typical stress responses. Primary neuronal cultures or differentiated motor neuron-like cells will be used with G3BP1/2 knocked down via siRNA or genetically deleted using CRISPR. The experimental design specifically avoids sodium arsenite or heat shock protocols that induce stress granules, instead focusing on conditions where TDP-43 aggregation occurs through intrinsic propensity or cellular aging processes. Aggregation will be quantified using filter trap assays, immunocytochemistry for phosphorylated TDP-43, and biochemical fractionation to separate soluble from insoluble protein pools. This approach will reveal whether G3BP proteins have aggregation-promoting roles beyond their stress granule functions. This experiment directly tests predictions arising from the following hypotheses: - **Stress Granule Phase Separation Modulators** - **Phase-Separated Organelle Targeting** - **RNA Granule Nucleation Site Modulation** - **Mitochondrial RNA Granule Rescue Pathway** - **Axonal RNA Transport Reconstitution** ## Experimental Protocol **Phase 1: Cell Culture Preparation (Days 1-3)** • Maintain HEK293T, SH-SY5Y, and primary cortical neurons in appropriate media • Transfect cells with TDP-43 wildtype, A315T, and M337V constructs using Lipofectamine 3000 • Generate stable G3BP1/G3BP2 knockout cell lines using CRISPR-Cas9 (n=3 clones per line) • Validate knockout efficiency by Western blot and qRT-PCR **Phase 2: G3BP Inhibition and TDP-43 Expression (Days 4-7)** • Treat cells with G3BP inhibitors: C108 (10-50 μM), ISRIB (200 nM), or siRNA knockdown • Express TDP-43 constructs for 24-48 hours to induce aggregation • Avoid stress conditions (no arsenite, heat shock, or oxidative stress) • Monitor cell viability using MTT assay and trypan blue exclusion **Phase 3: TDP-43 Aggregation Analysis (Days 8-10)** • Fix cells at 24, 48, and 72 hours post-transfection • Perform immunofluorescence using anti-TDP-43 (1:500) and anti-G3BP1 (1:200) antibodies • Quantify cytoplasmic TDP-43 aggregates >1 μm diameter per cell (n≥200 cells/condition) • Assess nuclear TDP-43 clearance by measuring nuclear/cytoplasmic fluorescence ratio • Perform filter trap assays to quantify insoluble TDP-43 aggregates **Phase 4: Stress Response Assessment (Days 11-14)** • Subject cells to mild physiological stresses: 42°C heat shock (30 min), 100 μM H2O2 (1 hour), 1 μM tunicamycin (4 hours) • Measure cell survival by ATP luminescence and caspase-3/7 activity • Analyze stress response gene expression (HSP70, CHOP, XBP1) by qRT-PCR • Assess protein synthesis recovery using puromycin incorporation assay **Phase 5: Alternative Nucleator Testing (Days 15-18)** • Overexpress alternative stress granule nucleators: CAPRIN1, USP10, or UBAP2L • Co-transfect with TDP-43 constructs in G3BP-deficient cells • Quantify rescue of stress response functionality • Measure formation of ribonucleoprotein granules using FISH for specific mRNAs ## Expected Outcomes 1. **TDP-43 aggregation will persist in G3BP-inhibited cells**, with ≥70% of transfected cells showing cytoplasmic aggregates regardless of G3BP status, demonstrating aggregation independence from stress granule machinery 2. **G3BP inhibition will impair cellular stress responses** by 40-60%, with reduced survival rates (p<0.01) and delayed protein synthesis recovery following physiological stress exposure 3. **Nuclear TDP-43 clearance will be unaffected by G3BP status**, maintaining similar nuclear depletion kinetics (50-70% reduction within 48 hours) across all treatment conditions 4. **Alternative stress granule nucleators will partially rescue stress responses** in G3BP-deficient cells, restoring 30-50% of normal stress tolerance when overexpressed 5. **Insoluble TDP-43 aggregate formation will show <20% difference** between G3BP-sufficient and G3BP-deficient conditions, measured by filter trap assay 6. **Cell viability under basal conditions will remain >85%** in G3BP-inhibited cells expressing TDP-43, indicating that aggregation toxicity is independent of G3BP-mediated pathways ## Success Criteria • **Statistical significance threshold**: p<0.05 for all comparisons with n≥3 biological replicates and ≥200 cells analyzed per condition • **TDP-43 aggregation independence**: <30% difference in aggregate formation between G3BP-sufficient and G3BP-deficient conditions across all TDP-43 variants • **Stress response impairment**: ≥30% reduction in stress survival or protein synthesis recovery in G3BP-inhibited cells compared to controls • **Knockout validation**: ≥90% reduction in G3BP1/G3BP2 protein levels confirmed by Western blot in all knockout clones used • **Functional rescue criteria**: Alternative nucleators must restore ≥25% of normal stress response functionality to be considered functionally relevant • **Reproducibility requirement**: Key findings must be replicated across at least 2 different cell types (HEK293T and neuronal cells) with consistent directional effects
PRIMARY OUTCOME
Quantification of insoluble TDP-43 aggregates using filter trap assays and biochemical fractionation in G3BP-deficient cells under non-stress granule inducing conditions compared to controls.
EXPECTED OUTCOMES
1. **TDP-43 aggregation will persist in G3BP-inhibited cells**, with ≥70% of transfected cells showing cytoplasmic aggregates regardless of G3BP status, demonstrating aggregation independence from stress granule machinery 2. **G3BP inhibition will impair cellular stress responses** by 40-60%, with reduced survival rates (p<0.01) and delayed protein synthesis recovery following physiological stress exposure 3. **Nuclear TDP-43 clearance will be unaffected by G3BP status**, maintaining similar nuclear depletion kinetics (50-70% reduction within 48 hours) across all treatment conditions 4. **Alternative stress granule nucleators will partially rescue stress responses** in G3BP-deficient cells, restoring 30-50% of normal stress tolerance when overexpressed 5. **Insoluble TDP-43 aggregate formation will show <20% difference** between G3BP-sufficient and G3BP-deficient conditions, measured by filter trap assay 6. **Cell viability under basal conditions will remain >85%** in G3BP-inhibited cells expressing TDP-43, indicating that aggregation toxicity is independent of G3BP-mediated pathways
SUCCESS CRITERIA
• **Statistical significance threshold**: p<0.05 for all comparisons with n≥3 biological replicates and ≥200 cells analyzed per condition • **TDP-43 aggregation independence**: <30% difference in aggregate formation between G3BP-sufficient and G3BP-deficient conditions across all TDP-43 variants • **Stress response impairment**: ≥30% reduction in stress survival or protein synthesis recovery in G3BP-inhibited cells compared to controls • **Knockout validation**: ≥90% reduction in G3BP1/G3BP2 protein levels confirmed by Western blot in all knockout clones used • **Functional rescue criteria**: Alternative nucleators must restore ≥25% of normal stress response functionality to be considered functionally relevant • **Reproducibility requirement**: Key findings must be replicated across at least 2 different cell types (HEK293T and neuronal cells) with consistent directional effects
PROTOCOL
**Phase 1: Cell Culture Preparation (Days 1-3)** • Maintain HEK293T, SH-SY5Y, and primary cortical neurons in appropriate media • Transfect cells with TDP-43 wildtype, A315T, and M337V constructs using Lipofectamine 3000 • Generate stable G3BP1/G3BP2 knockout cell lines using CRISPR-Cas9 (n=3 clones per line) • Validate knockout efficiency by Western blot and qRT-PCR **Phase 2: G3BP Inhibition and TDP-43 Expression (Days 4-7)** • Treat cells with G3BP inhibitors: C108 (10-50 μM), ISRIB (200 nM), or siRNA knockdown • Express TDP-43 constructs for 24-48 hours to induce aggregation • Avoid stress conditions (no arsenite, heat shock, or oxidative stress) • Monitor cell viability using MTT assay and trypan blue exclusion **Phase 3: TDP-43 Aggregation Analysis (Days 8-10)** • Fix cells at 24, 48, and 72 hours post-transfection • Perform immunofluorescence using anti-TDP-43 (1:500) and anti-G3BP1 (1:200) antibodies • Quantify cytoplasmic TDP-43 aggregates >1 μm diameter per cell (n≥200 cells/condition) • Assess nuclear TDP-43 clearance by measuring nuclear/cytoplasmic fluorescence ratio • Perform filter trap assays to quantify insoluble TDP-43 aggregates **Phase 4: Stress Response Assessment (Days 11-14)** • Subject cells to mild physiological stresses: 42°C heat shock (30 min), 100 μM H2O2 (1 hour), 1 μM tunicamycin (4 hours) • Measure cell survival by ATP luminescence and caspase-3/7 activity • Analyze stress response gene expression (HSP70, CHOP, XBP1) by qRT-PCR • Assess protein synthesis recovery using puromycin incorporation assay **Phase 5: Alternative Nucleator Testing (Days 15-18)** • Overexpress alternative stress granule nucleators: CAPRIN1, USP10, or UBAP2L • Co-transfect with TDP-43 constructs in G3BP-deficient cells • Quantify rescue of stress response functionality • Measure formation of ribonucleoprotein granules using FISH for specific mRNAs
Source: debate_extraction
🧫 Experiment Extras
ESTIMATED COST
$80,000
TIMELINE
5 months
MARKET PRICE
$0.46
STATUS
proposed
Scoring Dimensions
Info Gain 0.50 (25%) Feasibility 0.50 (20%) Hyp Coverage 0.50 (20%) Cost Effect. 0.50 (15%) Novelty 0.50 (10%) Ethical Safety 0.50 (10%)0.400composite
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.